INTRODUCTION
Coronary heart disease (CHD) is a major public health concern; it is the leading cause of mortality worldwide, accounting for more than 7 million deaths each year [1] . The majority of CHD-related deaths are due to acute coronary syndrome (ACS) or resulting complications [2, 3] . In Sweden, 1 in 4 deaths are estimated to be due to ACS [4] . ACS is based on the underlying pathophysiology of thrombosis, which is induced by the rupture or erosion of vulnerable coronary plaque. Such a rupture will cause the formation of a blood clot, which subsequently blocks the artery, leading to a sudden or substantial reduction in the coronary blood flow. Manifestations of ACS typically fall into three categories: ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI) and unstable angina (UA). All three are associated with a (very) high, moderate and (very) low degree of obstruction to myocardial perfusion and severity of myocardial ischemia, respectively. Electrocardiograms (ECGs) and cardiac biomarkers (e.g., troponin) can be used to differentiate between the types of ACS (i.e., between [N]STEMI and UA) and these play a crucial role in risk stratification because biomarker elevation can help to identify myocardial cellular damage and potentially predict short-term outcomes of subsequent myocardial infarction (MI) and death [5, 6] .
Current European guidelines recommend
dual antiplatelet therapy of acetylsalicylic acid (ASA) plus a P2Y 12 inhibitor (i.e., ticagrelor, prasugrel, ticlopidine or clopidogrel) to reduce the risk of thrombus formation in ACS patients [7, 8] . Dual antiplatelet therapy has proven efficacy in reducing the likelihood of secondary cardiovascular (CV) events, with an increase in the rate of major bleeding [8] . Despite such 'dual antiplatelet' prophylaxis, 20% of patients die within 5 years of an ACS event. The vast majority of these deaths occur after discharge from hospital for the initial ACS event (the index event) [5, 9] . To further reduce this burden, several novel oral anticoagulants (apixaban, dabigatran and rivaroxaban) have been investigated for the prevention of secondary events in the ACS indication [8, 10, 11] . 
METHODS
The current study consists of a costeffectiveness analysis (CEA) of secondary prevention in adult ACS patients with elevated cardiac biomarkers without a prior history of stroke or TIA. This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors.
Patients enter the model following stabilization of their ACS event which is defined according to the ATLAS ACS-TIMI 51 study as the time, up to 7 calendar days after the subject has been hospitalized for the index Clinical event risks, safety and treatment discontinuation rates from the ATLAS ACS 2-TIMI 51 trial, combined with real-world evidence to estimate event rates beyond the trial period, were used to evaluate the long-term cost-effectiveness of treating patients with rivaroxaban 2.5 mg BID in combination with ST-APT. The clinical data, used to inform the first 2 years of the model, were estimated from the intent-to-treat (ITT) trial population, comprising adult patients with elevated cardiac biomarkers without a prior history of stroke or TIA, which represents the European label for rivaroxaban. A maximum treatment duration of 2 years was assumed for rivaroxaban 2.5 mg BID in the analysis. To comply with current clinical guidelines for ACS, the maximum treatment duration for clopidogrel or ticlopidine in both arms of the analysis was 1 year [7, 8] .
Model Structure
With consideration of ESC guidelines [8] [20] . A full and detailed description of each health state, and how patients may transition between these, is provided in Table 1 .
The model considered 12 weekly cycles in the first 2 years (observation period) in line with study visits in ATLAS ACS 2-TIMI 51, and 6 monthly cycles thereafter (extrapolation period), to allow for variable transition probabilities, costs and utilities as patients recover from the initial event and their risk of secondary events decreases [21] . A half-cycle correction was applied to reflect the continuous nature of the occurrence of transitions during each cycle by assuming that, on average, all transitions occur halfway through any particular cycle. At the end of each model cycle, patients remained in their current health state, experienced a subsequent CV event or died. After an event, patients accrued additional costs and utility decrements in subsequent cycles until they transitioned to a new health state. The model distinguished between three phases within each non-fatal health state: a period comprising the first 6 months after the event, a period comprising the second 6 months after the event, and subsequent 6-month periods (post 12 months). Therefore, the first two phases were incorporated as tunnel states in which patients can remain for one (6-month) cycle only.
Model Assumptions
The model assumed there was no treatment effect associated with rivaroxaban or clopidogrel or ticlopidine after treatment discontinuation. In line with treatment guidelines, ASA monotherapy was assumed to be continued after discontinuation of all other treatment(s) for the remainder of the model.
Rivaroxaban was assumed to be prescribed for a maximum of 2 years. Clopidogrel and ticlopidine were assumed to be discontinued in both treatment arms after 1 year. As ticlopidine is not available in Sweden for the treatment of ACS patients, it was assumed that all patients who received ticlopidine in the ATLAS ACS 2-TIMI 51 clinical trial (\1% of patients) were subsequently treated with clopidogrel, without affecting the overall clinical outcomes. Different assumptions regarding post-event treatment discontinuation rates were applied to the first 12 months and subsequent 12 months of the modeled time period.
• Discontinuations of rivaroxaban and/or clopidogrel or ticlopidine for the first year were reflective of the discontinuation rates observed in the clinical trial.
• Based on expert opinion, rivaroxaban discontinuation in the second year of treatment is predicted to be higher in reallife practice than observed in the clinical study.
• During the second year of treatment, an overall discontinuation rate of 81% was assumed. Efficacy and treatment costs for rivaroxaban in the second year of the model were adjusted accordingly. This assumption is conservative and reflective of the informed decision about therapy physicians make in the second year of treatment.
Revascularization and non-ICH bleeding events were assumed to only occur during the observation period (in accordance with the specified length of treatment in each arm) as the rates would be considered equal after rivaroxaban and ST-APT discontinuation, and their impact on the incremental outcomes negligible after the observation period. The disutility associated with these events does not exceed one model cycle length (12 weeks) and were therefore not modeled as separate health states.
Model Setting
The CEA was performed from a Swedish societal perspective. The model was run for 40 years after which less than 1% of patients were still alive (lifetime horizon). All future costs and health outcomes were discounted at a rate of 3.0% per year, as recommended by the Swedish guidelines for economic evaluations [22] . Costs were expressed in Swedish Krona (SEK) at 2013 prices using the Consumer Price Index (CPI) to inflate costs where relevant [23] . Direct costs were captured in the form of direct medical costs related to antithrombotic treatment and secondary events. Indirect costs were captured in the form of productivity losses and costs of additional life years, constituting a conservative approach given the age of patients in the model [24] [25] [26] [27] . All costs were also expressed in Euros (€1 = SEK 8.8561, exchange rate taken on January 3, 2014) using foreign exchange rates taken from the European Central Bank (ECB) [28] .
Transition Probabilities
Clinical data from the ATLAS ACS 2-TIMI 51 trial in adults with elevated cardiac biomarkers without a prior history of stroke/TIA show a statistically significant reduction in the combined primary endpoint of CV death, MI or stroke, with rivaroxaban 2.5 mg twice daily versus placebo (HR = 0.80, 95% CI = 0.68-0.94). These data have been reported elsewhere [20] . Patient-level data considering each event type separately were used to estimate transition probabilities for the model. In doing so, both clinical benefits (such as are seen in the case of MIs) and increased risks of events (such as with HS/ICH events) are appropriately modeled. The data were interpolated using a parametric, Weibull-based survival analysis to generate consistent cycle-dependent transition probabilities, adjusting for potentially distorting patient drop-out as observed in the trial (i.e., survival progression after an event within the later trial observations was not considered truly reflective of real-world survival due to low patient numbers comprising those later trial observations, thereby resulting in inconsistent estimates for [29] .
To capture long-term survival rates, transition probabilities on the effectiveness and safety of ASA were extrapolated assuming constant rates in time. The Weibull distribution, chosen to reflect the fact that patient risk decreases over time following a qualifying event, is time dependent and was used to estimate transition probabilities for each 12-week cycle within the observation period. Therefore, an average estimate over multiple cycles in which to base the extrapolation period was not required. The last observation from the control arm of the observation period is used to estimate transition probabilities applied in the extrapolation period, with the RRR calculated from CURE used to model transition probabilities based on ASA monotherapy use in the long term.
Furthermore, event rates applied in the extrapolation period were based on, and corrected for, the increased risk of events due to aging, initial case fatalities and the reduction in relative risk of experiencing subsequent events over time. Swedish life tables provided probabilities of non-CV death for patients aged 62 years (using an elimination method) [30, 31] .
In an aging population, patients with ACS are at an increased risk of experiencing subsequent CV events or developing comorbidities that may contribute to the onset of future events [6, 32] . The annual age-specific risks of experiencing fatal and non-fatal events were taken from Swedish sources ( Table 2) .
Patients who have experienced an ACS event are at an elevated risk of experiencing a subsequent event, typically within the first 6 months following an event, although this risk diminishes over time [33] . The risk of suffering a second subsequent event after the first is assumed to be 1.5 times the risk of suffering a first subsequent event after the index event [33] . Initial case fatalities (proportion of fatal events typically within 28-30 days of onset) taken from the ATLAS ACS 2-TIMI 51 
Resource Use and Costs
The cost of non-fatal MI events is estimated based on the mean cost per patient taken from a paper which estimates costs from a Swedish register, accounting for administrative costs, hospitalizations, diagnostic work-ups, interventions and rehabilitation [36] . The proportion of costs allocated to the first 6 months, second 6 months and post 12 month periods following an event were based on those reported by Heeg et al. [21] . The cost of non-fatal IS was calculated based on the gender-weighted average costs incurred during an inpatient stay, during outpatient healthcare, and municipal care after a stroke event within the first year [37] . Cost estimates using this information were then applied to the second year after a stroke event. In the absence of specific, separate costs for IS and HS/ICH, the costs were assumed to be the same for the stroke types. Costs for non-fatal/non-ICH bleeding, revascularization and all fatal events (except non-CV death) were taken from the the lowest available prices in February 2013 were used for generic medications [39] . The daily drug price is multiplied by the number of days per model cycle and applied to each living patient within the specified treatment duration (Table 3) . Indirect costs included productivity losses due to the events, calculated using the human capital method (HCM) as prescribed by the Swedish authority [22] , and the cost of survival from added life years. The HCM assumes that all productivity loss due to disease can be accounted for as indirect costs and reflects the fact that short-term absence from work due to medical visits as well as due to events of ACS patients lead to (indirect) costs for society. This method is applicable to all patients under the national age of retirement (65 years in Sweden) [40] . The cost of daily productivity loss is given by aÂ12 365
where a is the average monthly salary (SEK 29,000) [22] , b 1 is the employer benefit (31.42%) [26] and b 2 is the union benefit (10%) [26] . The resulting daily cost of SEK 1388 (€152) is then multiplied by the number of days of productivity loss assumed per event (Table 4 ). The cost of added life years takes into account the difference between consumption and production for patients of each modeled age category ( Table 5 ). The costs The lengths of disutility associated with bleeding and revascularization events were based on literature and expert opinion, and were assumed to be 30 days for TIMI major bleeding and PCI, 2 days for TIMI minor bleeding and TIMI bleeding requiring medical attention, and 84 days for CABG [15] [16] [17] . The proportion of patients suffering an event, multiplied by the respective disutility corrected for event-specific duration of quality of life impact, was deducted from the overall quality of life model outcomes. The utility values applied in the model are provided in Table 6 . TIMI major bleed 28 [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] Patients are recommended to take 4 weeks sick leave for surgery of perforated peptic ulcer in accordance with the assumption that major bleed is defined by a GI bleed [38] TIMI minor bleed 0.5 0.4-0.6 Assumption based on absence from work due to a healthcare visit TIMI bleed requiring medical attention 0.5 0.4-0.6 Assumption based on absence from work due to a healthcare visit CABG coronary artery bypass graft, DRG diagnosis related group, GI gastrointestinal, HS hemorrhagic stroke, ICH intracranial hemorrhage, IS ischemic stroke, MI myocardial infarction, NCD non-cardiovascular death, OCD other cardiovascular death, PCI percutaneous coronary intervention, TIMI thrombolysis in myocardial infarction (Fig. 3b) , for which a regression analysis based on the results of the PSA was used to determine the upper and lower bounds of risk per event type (i.e., MI, IS, HS/ICH, CV death) when applying a 95% confidence interval. Plus and minus 25% of the deterministic value offers in almost all cases a much wider interval than would be seen if the interval was based on TIMI major bleeding 0.750 0.563-0.938 GI bleeds (14 days duration) [15] TIMI minor bleeding 0.800 0.600-1.000 Minor bleeding (2 days duration) [16] TIMI bleed requiring medical attention 0.800 0.600-1.000 Minor bleeding (2 days duration) [16] CABG coronary artery bypass graft, GI gastrointestinal, HS hemorrhagic stroke, ICH intracranial hemorrhage, IS ischemic stroke, MI myocardial infarction, NCD non-cardiovascular death, OCD other cardiovascular death, PCI percutaneous coronary intervention, TIMI thrombolysis in myocardial infarction 
RESULTS

Base-Case Analysis
The base-case cost-effectiveness results are summarized in Table 7 . Based on the model, 
Sensitivity analyses
Uncertainty around the cost-effectiveness results was demonstrated by plotting simulations from the PSA on a costeffectiveness plane as presented in Fig. 2a . Almost all of the probabilistic simulations (92.6%) suggest a QALY gain with rivaroxaban, with an associated increase in cost (upper righthand quadrant of the figure). The probability of rivaroxaban being cost-effective at a willingness-to-pay threshold of SEK 500,000 (€56,458) is estimated to be [99.9% (Fig. 2b) . Univariate sensitivity analyses were performed on all model variables and the results are presented in Fig. 3 . The tornado graphs show that the base-case analysis was robust to plausible changes in the input parameters, with a majority of the parameters having minimal impact on the overall ICER (Fig. 3a) . In the efficacy-related analysis (Fig. 3b) , the results were most sensitive to changes in the difference of other CV death rates between the rivaroxaban 2.5 mg BID ? ST-APT and ST-APT alone arms. This is not unexpected as there is a significant CV mortality benefit associated with rivaroxaban [11] . 
DISCUSSION
The result from this study demonstrated that, To best reflect the current situation in Sweden, the most recent data from each database were used, with at least one data year included to ensure robustness of model inputs.
However, the approach presented here is not without its limitations. The model provides a simplification of what is expected in reality.
Long-term outcomes believed to reflect the consequences of therapy in ACS patients were based on a number of assumptions to capture natural disease progression. Treatment durations of 2 years for rivaroxaban and 1 year for clopidogrel or ticlopidine were assumed to reflect ESC guidelines [7, 8] ; a RRR from the CURE trial [29] was applied to both treatment arms to adjust for the removal of clopidogrel or ticlopidine treatment effect after 1 year. Manual adjustments to discontinuation rates in the rivaroxaban arm were required for the second year of treatment to ensure alignment with expectations on the use of rivaroxaban in clinical practice. There is currently no data available on the real-life use of rivaroxaban in this patient population. As such, the discontinuation adjustments applied in the evaluation are based on expert opinion. Further, the model does not consider the longterm impact of non-fatal/non-ICH bleeding events beyond the duration of treatment as this was believed to have marginal impact on the overall model outcomes. In the absence of specific HS/ICH estimates, the costs and utilities applied to patients experiencing IS were also applied to those with HS/ICH.
CONCLUSION
The analysis suggests that rivaroxaban 2.5 mg BID provides a cost-effective treatment strategy in a Swedish societal setting for the secondary prevention of ACS in patients with elevated biomarkers without prior stroke/TIA, mainly driven by a benefit in terms of reduced mortality as demonstrated in the ATLAS ACS 2-TIMI 51 trial. This analysis may help to support the combination of ST-APT and rivaroxaban 2.5 mg BID for the secondary prevention of ACS events, as recommended by the ESC STEMI guidelines in patients with low bleeding risk [8] . The conclusion of costeffectiveness holds, regardless of the standard of care currently being received by the patient (ASA monotherapy or ASA ? clopidogrel or ticlopidine).
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